BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30721028)

  • 1. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.
    Kadiyala P; Li D; Nuñez FM; Altshuler D; Doherty R; Kuai R; Yu M; Kamran N; Edwards M; Moon JJ; Lowenstein PR; Castro MG; Schwendeman A
    ACS Nano; 2019 Feb; 13(2):1365-1384. PubMed ID: 30721028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic HDL Nanoparticles Delivering Docetaxel and CpG for Chemoimmunotherapy of Colon Adenocarcinoma.
    Scheetz LM; Yu M; Li D; Castro MG; Moon JJ; Schwendeman A
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas.
    Scheetz L; Kadiyala P; Sun X; Son S; Hassani Najafabadi A; Aikins M; Lowenstein PR; Schwendeman A; Castro MG; Moon JJ
    Clin Cancer Res; 2020 Aug; 26(16):4369-4380. PubMed ID: 32439701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
    Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
    Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Delivery of an Adjuvant CXCR4-CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy.
    Alghamri MS; Banerjee K; Mujeeb AA; Mauser A; Taher A; Thalla R; McClellan BL; Varela ML; Stamatovic SM; Martinez-Revollar G; Andjelkovic AV; Gregory JV; Kadiyala P; Calinescu A; Jiménez JA; Apfelbaum AA; Lawlor ER; Carney S; Comba A; Faisal SM; Barissi M; Edwards MB; Appelman H; Sun Y; Gan J; Ackermann R; Schwendeman A; Candolfi M; Olin MR; Lahann J; Lowenstein PR; Castro MG
    ACS Nano; 2022 Jun; 16(6):8729-8750. PubMed ID: 35616289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy.
    Kuai R; Yuan W; Son S; Nam J; Xu Y; Fan Y; Schwendeman A; Moon JJ
    Sci Adv; 2018 Apr; 4(4):eaao1736. PubMed ID: 29675465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
    Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
    Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-density lipoprotein-biomimetic nanocarriers for glioblastoma-targeting delivery: the effect of shape.
    Huang JL; Jiang G; Song QX; Gu X; Song HH; Wang XL; Jiang D; Kang T; Feng XY; Jiang XG; Chen HZ; Gao XL
    Pharmazie; 2016 Dec; 71(12):709-714. PubMed ID: 29441999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy.
    Kadari A; Pooja D; Gora RH; Gudem S; Kolapalli VRM; Kulhari H; Sistla R
    Eur J Pharm Biopharm; 2018 Nov; 132():168-179. PubMed ID: 30244167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates.
    Najafabadi AH; Abadi ZIN; Aikins ME; Foulds KE; Donaldson MM; Yuan W; Okeke EB; Nam J; Xu Y; Weerappuli P; Hetrick T; Adams D; Lester PA; Salazar AM; Barouch DH; Schwendeman A; Seder RA; Moon JJ
    J Control Release; 2021 Sep; 337():168-178. PubMed ID: 34280415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy.
    Chang Y; Cai X; Syahirah R; Yao Y; Xu Y; Jin G; Bhute VJ; Torregrosa-Allen S; Elzey BD; Won YY; Deng Q; Lian XL; Wang X; Eniola-Adefeso O; Bao X
    Nat Commun; 2023 Apr; 14(1):2266. PubMed ID: 37080958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
    Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.
    Reichel D; Sagong B; Teh J; Zhang Y; Wagner S; Wang H; Chung LWK; Butte P; Black KL; Yu JS; Perez JM
    ACS Nano; 2020 Jul; 14(7):8392-8408. PubMed ID: 32551496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme.
    Nikanjam M; Gibbs AR; Hunt CA; Budinger TF; Forte TM
    J Control Release; 2007 Dec; 124(3):163-71. PubMed ID: 17964677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma.
    Jiang S; Li W; Yang J; Zhang T; Zhang Y; Xu L; Hu B; Li Z; Gao H; Huang Y; Ruan S
    ACS Nano; 2024 Feb; 18(8):6445-6462. PubMed ID: 38358804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy.
    Gong M; Zhang Q; Zhao Q; Zheng J; Li Y; Wang S; Yuan Y
    Drug Deliv; 2019 Dec; 26(1):708-716. PubMed ID: 31290708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
    Van Woensel M; Mathivet T; Wauthoz N; Rosière R; Garg AD; Agostinis P; Mathieu V; Kiss R; Lefranc F; Boon L; Belmans J; Van Gool SW; Gerhardt H; Amighi K; De Vleeschouwer S
    Sci Rep; 2017 Apr; 7(1):1217. PubMed ID: 28450700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy.
    Zhang Z; Xu X; Du J; Chen X; Xue Y; Zhang J; Yang X; Chen X; Xie J; Ju S
    Nat Commun; 2024 Feb; 15(1):1118. PubMed ID: 38320994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
    Zhang R; Wan Y; Lv H; Li F; Lee CS
    J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.